

Appendix B: Supplementary sensitivity analysis.

	Overt Hypothyroidism	Subclinical Hypothyroidism	Euthyroidism	Subclinical Hyperthyroidism	Overt Hyperthyroidism
Main model	0.67 (0.50-0.92)	0.88 (0.79-0.97)	1 (ref.)	1.30 (1.18-1.43)	1.41 (1.22-1.63)
Main model including time- dependent variables					
Any treatment	0.56 (0.42-0.79)	0.82 (0.74-0.92)	1 (ref.)	1.24 (1.13-1.37)	1.26 (1.08-1.47)
Methimazole	-	-		1.27 (1.15-1.40)	1.30 (1.09-1.54)
Levothyroxine	0.68 (0.49-0.94)	0.88 (0.79-0.98)	1 (ref.)	-	-
Stratified on follow-up					
3 months	0.36 (0.05-2.56)	0.74 (0.45-1.22)	1 (ref.)	1.03 (0.64-1.65)	2.66 (1.65-4.31)
6 months	0.41 (0.06-2.93)	0.90 (0.56-1.46)	1 (ref.)	0.79 (0.45-1.38)	2.72 (1.63-4.54)
12 months	0.69 (0.22-2.15)	1.03 (0.74-1.45)	1 (ref.)	1.65 (1.22-2.23)	1.33 (0.77-2.29)
Adjusted for known risk factors for AF					
Hypertension, heart failure, myocardial infarction, valvular heart disease and diabetes	0.68 (0.50-0.92)	0.89 (0.80-0.98)	1 (ref.)	1.31 (1.20-1.45)	1.42 (1.23-1.64)
Main model including time- dependent changes in thyroid function status	0.81 (0.67-0.98)	1.04 (0.94-1.15)	1 (ref.)	1.38 (1.27-1.51)	2.16 (1.84-2.54)
Main model including adjustment for 5-year Charlson Comorbidity Index	0.68 (0.50-0.92)	0.88 (0.80-0.97)	1 (ref.)	1.30 (1.18-1.43)	1.39 (1.20-1.62)